Global Cell Therapy Market to Grow at a CAGR of 23.27% to 2021 – Analysis Key Players (Dendreon, Mesoblast, and Vericel)

Market Research Nest – Cell Therapy Market adds “Global Cell Therapy Market 2017-2021” new reports to its research database. The report spread across 118 pages with tables and figures in it. adds “Global Cell Therapy Market 2017-2021” new reports to its research database. The report spread across 118 pages with tables and figures in it.

The research analysts forecast the global cell therapy market to grow at a CAGR of 23.27% during the period 2017-2021.

Cell therapy products, which are derived from stem cells, tissues, and organs grown in laboratories, are injected into patients. The growing number of clinical trials, government and private funding, and increasing number of partnerships between companies are driving the growth of the global cell therapy market. Cell therapy products that are available in the market are based on autologous and allogenic cells. The demand of cell therapy treatment is increasing. This is because cell therapy products can be used for personalized treatment.

Get more details aboutreportat

Technavio recognizes the following companies as the key players in the global cell therapy market: Dendreon, Mesoblast,  and Vericel.

Other Prominent Vendors in the market are: AlloCure, Amorcyte, Anterogen, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bellicum Pharmaceuticals, BioCardia, BIOCELLULAR THERAPIES, Biogen Idec, Bio-Tissue, BIOTIME, BioTissue Technologies, BrainStorm Cell Therapeutics, Bluebird Bio, Bone Therapeutics, Caladrius, Capricor Therapeutics, CellBioMed, Celgene, Cell Medica, CellPraxis, CellSeed, Cell Therapy, Celyad, CESCA THERAPEUTICS, CRC for Cell Therapy Manufacturing, CryoLife, Cynata Therapeutics, Cytori Therapeutics, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra Life Sciences, Intercytex, iSTO Technologies, Janssen Pharma, Juno Therapeutics, Juventas Therapeutics, Kensey Nash, Kite Pharma, Kiadis Pharma, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Nanofiber Solutions, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa Therapeutics, Orbsen Therapeutics, Pfizer, Pharmicell, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, Regenerexx, Regeneus, Regenerys, Regience, Regrow, RepliCel, ReproCELL, ReNeuron, RenovaCare, RESSTORE, RhinoCyte, Rohto Pharmaceutical, SanBio, Sangamo BioSciences, Shanghai Sunway Biotechm, Shire Regenerative Medicine, StemCells, STEMPEUTICS RESEARCH, Synergistic Technologies, t2cure, Takara Bio, Tella, Tengion, TissueGene, Tessa Therapeutics, Txcell, VentriNova, ViaCyte, VistaGen Therapeutics, and SDRMI and Xcelthera.

The latest trend gaining momentum in the market is Proliferation of strategic alliances and royalty payments. Strategic alliances have affected the growth of the market in emerging regions such as APAC. Several vendors prefer M&A to strengthen their global position and improve their commercial capabilities. Through strategic alliances, many companies are receiving upfront and royalty payments, which they use for R&D to develop novel regenerative medicine products.

Order a Purchase Report Copy at . (This is premium report, Single User License – USD 3500 and Five User License – USD 4000)

According to the report, one of the major drivers for this market is Increase in prevalence of chronic diseases. The prevalence of chronic diseases such as diabetes and CVDs is growing. Diabetes causes diabetic retinopathy and diabetic foot ulcer. CVDs such as coronary heart disease (CHD) can cause stroke. The increase in prevalence of chronic diseases increases the cost burden on healthcare systems. For instance, according to the CDC, in February 2010, stroke and heart disease cost the Government of the US around $315.4 billion. Cell therapy products can treat such diseases and reduce the economic burden on healthcare systems.

Further, the report states that one of the major factors hindering the growth of this market is High cost of clinical trials and cell therapy doses. The cost of clinical trials and product launches can increase the cost burden on manufacturers. Most companies that offer cell therapy products are small. Such companies require government or private funding. However, most organizations provide limited funding only if the target goal is achieved.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. 

Inquiry before buy this report at .

About Us: is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us

Mr. Jeet Jain

Sales Manager

+1-240-284-8070 / +44-20-3290-4151

Connect with us:  Google+Twitter

Media Contact
Company Name: GRN Research Private Limited
Contact Person: Jeet Jain
Email: Send Email
Phone: +12402848070
Address:10, Varshanand Housing Society, Anand Nagar, Sinhagad Road
City: Pune
State: Maharshtra
Country: India